NCT03095807View on ClinicalTrials.gov

Investigation of Single Ascending Doses of NNC9204-1706 in Male Subjects Being Overweight or With Obesity

PHASE1CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

March 20, 2017

Primary Completion Date

August 31, 2017

Study Completion Date

August 31, 2017

Conditions
Metabolism and Nutrition DisorderObesity
Interventions
DRUG

NNC9204-1706 A

Administered subcutaneously (s.c., under the skin) Up to 7 dose cohorts will be investigated.

DRUG

Placebo

Administered subcutaneously (s.c., under the skin)

Trial Locations (1)

21225

Novo Nordisk Investigational Site, Baltimore

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY